In 2014, the National Multiple Sclerosis Society invested $50.6 million in 380 new and ongoing research projects and initiatives. Here is a brief summary of the research highlights reflecting the Society's commitment to pursue promising ... Red Orbit, 1 month ago
MS Research Highlights In 2014 That Offer New Leads In Stopping MS, Restoring Function Lost, And Ending MS Forever - Pharmacy Times, 1 month ago
1 images for "harvard bone marrow initiative"
Cells could be exploited to treat osteoarthritis and osteoporosis A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The discovery by researchers at Columbia University Medical Center (CUMC) is ...Health Canal, 1 week ago
SANTA CLARA, CA -- (Marketwired) -- 01/28/15 -- Iris BioTechnologies Inc. (OTCQB: IRSB), a life sciences company poised to set new personalized medicine standards for precision diagnosis and therapy, is pleased to welcome Dr. Douglas Hendren , Dr.4 Traders, 5 hours ago Iris BioTechnologies Welcomes New Board Member and Key Employees AndhraNews.net, 3 hours ago
Provectus' Novel Synthesis Patent Application Allowed by Chinese Patent Office; Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 26, 2015. Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) , a development-stage oncology and dermatology biopharmaceutical company ...BioMedReports, 1 day ago
Valeo, Tom Back to Top | Article Outline ARTICLE IN BRIEF A research team developed a mouse model of the JC virus, which suggests that the virus multiplies primarily in astrocytes, rather than oligodendrocytes. Neuroinfectious disease experts ...Neurology Today, 1 month ago
UPMC/University of Pittsburgh Schools of the Health Sciences PITTSBURGH, Dec. 17, 2014 - Warren Shlomchik, M.D., a leading expert in investigating the immunologic mechanisms underlying graft-versus-host-disease (GVHD), a common complication for some ...Noodls, 1 month ago
New Follow-Up Data for IMBRUVICA® (ibrutinib) Presented at ASH Show Longer Term Efficacy in Patients with..
/PRNewswire/ -- Data confirms consistency of IMBRUVICA as an effective treatment option for patients with these challenging blood cancers Note: This press release corresponds to ASH abstracts 3331 and 4453 Janssen-Cilag International NV ...ADVFN India, 1 month ago
More from: , Sys-Con Australia...and 1 other sources
PUBLIC RELEASE DATE: 7-Dec-2014 Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have ...EurekAlert!, 1 month ago
Original Article Stephen M. Ansell, M.D., Ph.D., Alexander M. Lesokhin, M.D., Ivan Borrello, M.D., Ahmad Halwani, M.D., Emma C. Scott, M.D., Martin Gutierrez, M.D., Stephen J. Schuster, M.D., Michael M. Millenson, M.D., Deepika Cattry, M.S., ...New England Journal of Medicine, 1 month ago
Published: December 5, 2014. Location, location, location goes the old real estate proverb but cancer also responds to its neighborhood, particularly in the physical surroundings of bone marrow cells where human myeloid leukemias arise and ...ScienceNewsline, 1 month ago
on your WebpageAdd Widget >Get your members hooked!